RxDoctor Payments Data

Edward Hirsch, MD

Infectious Disease · Coral Springs, FLNPI 1578554408

Payments from drug & device makers

$3,395in general payments, 2019–2025

Across 129 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$876
  • Merck$516
  • Cipla USA Inc.$361
  • AbbVie$255
  • Astellas Pharma US Inc$237
  • Insmed, Inc.$161
  • plus $990 from 13 others

What the payments were for

  • Food & beverage$3,26996%
  • Education$1274%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,395 in reported general payments places this provider in the 70th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$260,947
Medicare patients
323
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine26$80,881
DescovyEmtricitabine/Tenofov Alafenam36$78,254
BiktarvyBictegrav/Emtricit/Tenofov Ala13$53,119
ZerbaxaCeftolozane/Tazobactam12$49,321
JulucaDolutegravir/Rilpivirine12$40,979
Daptomycin21$28,592
ErtapenemErtapenem Sodium42$28,018
IsentressRaltegravir Potassium11$22,083
Vancomycin Hcl140$18,830
Meropenem34$14,161
Cefepime Hcl51$10,398
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam25$5,911
CeftriaxoneCeftriaxone Sodium78$5,838
Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod16$3,987
Vancomycin Hcl-0.9% NaclVancomycin/0.9 % Sod Chloride14$3,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadDescovy, Biktarvy$90$131,37349 claims
Viiv Healthcare CompanyDovato, Juluca$876$121,86038 claims
MerckZerbaxa, Isentress$516$71,40423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →